Timothy R. Mack

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 752 citations

Medicine, Oncology, Chemotherapy +13

Structural Analysis and Solution Studies of the Activated Regulatory Domain of the Response Regulator ArcA: A Symmetric Dimer Mediated by the α4-β5-α5 Face

A. Toro-Roman, Timothy R. Mack, Ann Stock · Journal of Molecular Biology · 2005 · 130 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +8

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · Blood · 2021 · 88 citations

Medicine, Immunology, Oncology +17

Domain Orientation in the Inactive Response Regulator <i>Mycobacterium tuberculosis</i> MtrA Provides a Barrier to Activation^,

Natalia Friedland, Timothy R. Mack, Minmin Yu et al. · Biochemistry · 2007 · 87 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Regulation of Response Regulator Autophosphorylation through Interdomain Contacts

Christopher M. Barbieri, Timothy R. Mack, Victoria Robinson et al. · Journal of Biological Chemistry · 2010 · 70 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17